Aggressive polychemotherapy for acute myelofibrosis

Eur J Haematol. 1990 Apr;44(4):213-9. doi: 10.1111/j.1600-0609.1990.tb00382.x.

Abstract

Acute myelofibrosis is a rare and still ill-defined disease. Based on morphological observation, immunophenotyping and ultrastructural analysis, we support the assumption that acute myelofibrosis is a malignant disorder mainly of the megakaryocytic lineage and is closely related to acute megakaryocytic/blastic leukaemia. Consequently, the 11 patients reported here were treated with aggressive polychemotherapy with combinations including daunorubicin and cytosine arabinoside and 6-thioguanin or VP16-213. 4 complete remissions, 2 partial remissions and 1 minor response were observed. Duration of aplasia was not significantly prolonged. These findings indicate that the use of aggressive polychemotherapy is feasible in acute myelofibrosis and results in a significant number of remissions.

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Bone Marrow / pathology
  • Cytarabine / administration & dosage
  • Cytarabine / therapeutic use*
  • Daunorubicin / administration & dosage
  • Daunorubicin / therapeutic use*
  • Drug Therapy, Combination
  • Erythrocyte Count
  • Female
  • Humans
  • Infusions, Intravenous
  • Injections, Intravenous
  • Male
  • Megakaryocytes / pathology
  • Middle Aged
  • Primary Myelofibrosis / blood
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / pathology
  • Thioguanine / administration & dosage
  • Thioguanine / therapeutic use*

Substances

  • Cytarabine
  • Thioguanine
  • Daunorubicin